Linked Data API

Show Search Form

Search Results

1135413
star this property registered interest false more like this
star this property date less than 2019-06-27more like thismore than 2019-06-27
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading IVF: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answers by the Parliamentary Under-Secretary of State for Health on 14 July 2014 (HC Deb, col 448W), Earl Howe on 3 December 2014 (HL273), and comments by the Parliamentary Under-Secretary of State for Health on 20 January 2016 (HC Deb, col 623WH), how the Human Fertilisation and Embryology Authority (HFEA) ensures that clinics follow National Institute for Health and Care Excellence guidelines on limiting the use of ovulation induction or ovarian stimulation agents to the lowest effective dose and duration of use without collecting information on the identity of drugs used in treatment, the dosage used and the associated regimen for ovarian stimulation at each licensed centre; and what would be needed for the HFEA to regulate the administration of drugs during in vitro fertilisation treatment. more like this
star this property tabling member printed
Lord Alton of Liverpool remove filter
unstar this property uin HL16734 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-10more like thismore than 2019-07-10
star this property answer text <p>The Human Fertilisation and Embryology Acts 1990 and 2008 do not provide for the regulation of the use or monitoring of medicines used in fertility treatment.</p><p>Medicines used in fertility treatment are licensed by the Medicines and Healthcare products Regulatory Agency. These medicines may be used in Human Fertilisation and Embryology Authority-licensed clinics or in other settings, for example by general practitioners.</p><p>Medicine prescribing is a matter of clinical judgement, taking account of the individual patient’s circumstances and professional guidance. It is the duty of every clinician to take into account the welfare and best interest of their patient when deciding on the appropriate treatment for them for any medical condition, in line with General Medical Council’s good medical practice guidance.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-07-10T15:09:39.493Zmore like thismore than 2019-07-10T15:09:39.493Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
738
unstar this property label Biography information for Lord Alton of Liverpool more like this
1011239
star this property registered interest false more like this
star this property date less than 2018-11-20more like thismore than 2018-11-20
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading IVF: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the Written Answers by Lord O’Shaughnessy on 15 November (HL11187 and HL11188), what data are recorded by the Medicines and Healthcare products Regulatory Agency’s pharmacovigilance work and the Yellow Card Scheme regarding drugs and dosages administered to women during IVF treatment and early pregnancy; to what extent this includes off-label drugs in order to monitor their long-term effects on women undergoing IVF treatment; how this compares to the collection of such data in other countries; and why the Human Fertilisation and Embryology Authority has no plans to establish a central database to monitor the long-term health implications of the medicines administered to women during IVF. more like this
star this property tabling member printed
Lord Alton of Liverpool remove filter
unstar this property uin HL11600 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-12-03more like thismore than 2018-12-03
star this property answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) continuously monitors all reports of suspected adverse drug reactions (ADRs) via the Yellow Card Scheme, including those reported in association with use for assisted reproduction such as in vitro fertilisation (IVF). These include reports of licensed and off-label use of medicines to suppress the natural menstrual cycle, medicines to prepare and stimulate the ovaries for ovulation, medicines at the time of egg collection and embryo transfer and medicines used to support the placenta during early pregnancy. The doses of each medicine used are set out in the product information of licensed medicines and are considered as part of the evaluation process when a potential safety concern is reviewed. A suspected ADR may be reported at any time after the medicine has been taken.</p><p>European Union legislation requires Member States to provide spontaneous reporting systems for ADRs to medicines. Such systems are widely used internationally for collection of suspected adverse reactions.</p><p>Data from the register of patients and treatments, maintained by the Human Fertilisation and Embryology Authority (HFEA), is already used for research on the long-term health implications of medicines administered during IVF. Among the research projects that have been conducted using HFEA register data are studies that looked at the cancer risk for women undergoing fertility treatment and children born as a result of assisted reproduction.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-12-03T15:14:43.053Zmore like thismore than 2018-12-03T15:14:43.053Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
unstar this property tabling member
738
unstar this property label Biography information for Lord Alton of Liverpool more like this
999743
star this property registered interest false more like this
star this property date less than 2018-11-01more like thismore than 2018-11-01
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading IVF: Drugs remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether they intend to establish a central database to track the long-term health effects of drugs administered to women undergoing IVF treatment; and if so, when. more like this
star this property tabling member printed
Lord Alton of Liverpool remove filter
unstar this property uin HL11188 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-15more like thismore than 2018-11-15
star this property answer text <p>Ovarian Hyperstimulation Syndrome (OHSS) is a well-recognised side effect of the medicines used to stimulate a patient’s ovaries during in vitro fertilisation (IVF) treatment. The risks of OHSS are taken very seriously and information on this condition and the symptoms to look out for must be provided to all patients. Patients are warned to contact their clinic or seek other medical assistance as soon as possible if they are concerned they may be developing any of the symptoms associated with the condition.</p><p>The Human Fertilisation and Embryology Authority (HFEA) requires all licensed clinics to report cases of severe or critical OHSS that come to their attention. OHSS, in its most severe form, can be fatal but deaths, as a result of the condition, are extremely rare in the United Kingdom with no deaths recorded since 2006. Hospital Episode Statistics suggest there are more emergency and out-of-hours admissions than are reported to the HFEA but there is evidence to suggest that many of these admissions have been incorrectly coded for OHSS when another condition was the reason for the admission.</p><p>The Government has no plans to establish a central database to monitor the long-term health implications of the medicines administered to women during IVF. However, we do track all adverse drug reactions assiduously, for example, through the Medicines and Healthcare products Regulatory Agency’s pharmacovigilance work and the Yellow Card Scheme.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN HL11187 more like this
star this property question first answered
less than 2018-11-15T16:19:58.077Zmore like thismore than 2018-11-15T16:19:58.077Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
unstar this property tabling member
738
unstar this property label Biography information for Lord Alton of Liverpool more like this